Somatostatin and Doxorubicin for Gallbladder Cancer
Author Information
Author(s): Li Ji-Yu, Quan Zhi-Wei, Zhang Qiang, Liu Jian-Wen
Primary Institution: Shanghai Jiao Tong University
Hypothesis
Does somatostatin enhance the effectiveness of doxorubicin in treating gallbladder cancer?
Conclusion
Somatostatin increases the sensitivity of gallbladder cancer cells to doxorubicin, leading to reduced cancer cell growth.
Supporting Evidence
- Somatostatin treatment led to cell cycle arrest in gallbladder cancer cells.
- Doxorubicin's effectiveness increased when combined with somatostatin.
- The IC50 value for doxorubicin decreased significantly with somatostatin co-treatment.
Takeaway
Using somatostatin with doxorubicin helps fight gallbladder cancer better than using doxorubicin alone.
Methodology
Gallbladder cancer cells were treated with somatostatin and doxorubicin, and their growth was measured in vitro and in a mouse model.
Limitations
The study had a small sample size and used high concentrations of somatostatin that may not be feasible for human use.
Participant Demographics
Gallbladder cancer cell line and nude mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website